Sign in
Create a Profile
Previous
An Open Label Assessment of Safety and Efficacy of Ruxolitinib (INCB018424) in Subjects with Primary Myelofibrosis, Post Essential Thromboythemia Myelofibrosis and Post Polycythemia Vera Myelofibrosis Who Have Platelet Counts of 50x109 /L to 100 x 109/L
Diseases and Conditions Researched
Post Essential Thromboythemia Myelofibrosis; Post Polycythemia Vera Myelofibrosis; Primary Myelofibrosis
Participation Guidelines
Gender: Both
Click here for detailed participation information for this trial.
| Sponsor: | Incyte Corporation |
|---|---|
| Study HIC#: | 1107008805 |
How will my information be used?
For more information about this trial, contact:
Yale Cancer Center
203-785-5702
How will my information be used?
When you express interest in a specific study, the information from your profile will be sent to the doctor conducting that study. If you're eligible to participate, you may be contacted by a nurse or study coordinator.
If you select a health category rather than a specific study, doctors who have active studies in that area may contact you to ask if you would like to participate.
In both cases, you will be contacted by the preferred method (email or phone) that you specified in your profile.
